Replies to post #1265 on Enanta Pharmaceuticals Inc (ENTA)

[NY1972]

Thank you for pointing that out. Are you surprised by Enta ventured into RSV graveyard? Could that be related to the discontinued HCV nucleoside program?


"AL-8176 is a nucleoside analog which is being developed by Alios BioPharma as an orally administered antiviral therapy for the treatment of infants infected with RSV. AL-8176 is designed to inhibit the replication of the RSV by acting on the viral polymerase. In vitro studies of the compound showed potent and highly selective inhibition of both RSV laboratory-adapted A and B strains as well as a range of diverse clinical isolates. Similar to other nucleoside analogs, AL-8176 demonstrates a high barrier to the development of viral resistance."